Okabe T et al. demonstrated that the synergistic effects of gefitinib and 5-fluorouracil combined treatment was only observed in EGFR mutant (exon 19 deletion) NSCLC cell lines with MET amplification but not in cell lines with an additional EGFR T790M mutation [35]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.